New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04725474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. About 263 adults with various solid cancers are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos
Pamplona, 31008, Spain
-
Hospital Universitari Vall d'Hebron, Institute of Oncology
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
ICMDiM, Hospital Clinic
Barcelona, 08036, Spain
-
ICO Hospitalet, Hospital Duran i Reynals
Barcelona, 08908, Spain
-
Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology
Sankt Gallen, 9007, Switzerland
-
Next Oncology, Phase I Unit. IOB - Hospital Quironsalud
Barcelona, 08023, Spain
-
START Madrid, Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
University Hospital Basel, Department for Medical Oncology
Basel, 4031, Switzerland
-
University Hospital Zurich, Department of Dermatology
Zurich, 9091, Switzerland
-
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik
Essen, 45147, Germany
-
Universitätsklinikum Frankfurt, Medizinische Klinik I
Frankfurt am Main, 60590, Germany
-
Universitätsklinikum Würzburg, Comprehensive Cancer Center
Würzburg, 97078, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a new antibody help the immune system fight advanced cancers?
- Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
- Can a cancer vaccine train the body to fight advanced tumors?